Open AccessRANKL Signaling Pathway: A Potential Target for Antiresorptive Therapy in Rheumatoid Arthritis
Author(s) -
Sidrah Anjum,
Attya Bhatti,
Fahd Qadir,
Usman Ashraf,
Peter John
Publication year - 2021
Publication title -
nust journal of natural sciences
Language(s) - English
Resource type - Journals
eISSN - 2710-222X
pISSN - 2072-4659
DOI - 10.53992/njns.v3i1.20
Subject(s) - rankl , rheumatoid arthritis , medicine , cancer research , signal transduction , bone resorption , osteoclast , immunology , receptor , biology , activator (genetics) , microbiology and biotechnology
Rheumatoid arthritis (RA) is a chronic polyarthritic autoimmune condition characterized by severe bone erosion. Osteoclasts, the bone resorbing cells, Rheumatoid arthritis (RA) is a chronic polyarthritic autoimmune condition characterized by severe bone erosion. Osteoclasts, the bone resorbing cells, are overly produced from the synovial inflammatory tissues in RA leading to excessive bone loss. RANKL-signaling pathway has been established to be the major pathway involved in osteoclastogenesis. This review highlights the role of around 40 osteoclastogenic factors involved in RANKL signaling and their potential to be targeted for antiresorptive therapy in RA. Furthermore, inhibitors of these proteins, which are already known to exhibit antiresorptive potential, have been reviewed. Elucidating new potential candidate therapeutic targets in the osteoclastogenesis pathway will open new avenues into the treatment and diagnosis of the arthritic conditionsare overly produced from the synovial inflammatory tissues in RA leading to excessive bone loss. RANKL-signaling pathway has been established to be the major pathway involved in osteoclastogenesis. This review highlights the role of around 40 osteoclastogenic factors involved in RANKL signaling and their potential to be targeted for antiresorptive therapy in RA. Furthermore, inhibitors of these proteins, which are already known to exhibit antiresorptive potential, have been reviewed. Elucidating new potential candidate therapeutic targets in the osteoclastogenesis pathway will open new avenues into the treatment and diagnosis of the arthritic conditions.